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1. Introduction
Diabetic neuropathy is a common microvascular complication of diabetes mellitus. Diabetic
neuropathy is a major risk factor for non-traumatic amputations and is thought to play a role
in the pathogenesis of other late complications of diabetes. The two major forms of diabetic
neuropathy include generalized neuropathy and autonomic neuropathy. Genreralized
neuropathy, affecting motor and sensory peripheral nerves can be subdivided further into
polyneuropathies which affect multiple nerves and focal neuropathies. The most common
form of generalized neuropathy is distal symmetrical polyneuropathy. Autonomic neuropathy
affects peripheral autonomic nerves. These autonomic nerves innervate most organ systems
of the body and the skin. Both distal symmetric polyneuropathy and autonomic neuropathy
cause substantial morbidity and are associated with a high risk of mortality. The hypothesized
mechanisms of diabetic neuropathy include ischemic effects caused by vascular abnormalities,
disruption of neuronal metabolism, axonal transport mechanisms and repair capabilities,
glycation of peripheral nervous system connective tissue, and glycation of Schwann cells or
extracellular matrix. In this chapter, we discuss the diagnostic criteria, pathophysiology,
epidemiology, and treatment of peripheral and autonomic neuropathy in type 1 diabetes.
2. Classification
Table 1 gives a detailed classification of the neuropathies observed in diabetes.
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3. Diabetic distal symmetric polyneuropathy in type 1 diabetes mellitus
3.1. Overview
Distal Symmetric Polyneuropathy (DSP) is the most common type of neuropathy affecting
patients with type 1 diabetes. Polyneuropathy is the greatest risk factor for non-traumatic
amputations and confers a higher mortality risk [3, 4]. The incidence of DSP increases with
duration of diabetes and with degree of hyperglycemia [5]. In type 1 diabetes, typically the
incidence of DSP is linked to other microvascular complications of nephropathy and retinop‐
athy [6]. Unlike type 2 diabetes, polyneuropathy is rarely if ever present in the first five years
of diagnosis. Metabolic memory in which improved metabolic control, even for a finite period,
confers improved outcomes in the future is a phenomenon which was discovered with the
Diabetes Complications and Control Treatment Trial, and may be an important factor to
consider in the treatment of type 1 diabetic patients [7].
3.2. Diagnostic criteria
The case definition of typical DSP or diabetic sensorimotor polyneuropathy from the American
Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic
Generalized Neuropathy Focal Neuropathies Autonomic Neuropathies
Typical: Distal symmetric
polyneuropathy (DSP) Compression: Cardiovascular autonomic neuropathy
Atypical Neuropathy: Median -carpal tunnel Gastrointestinal autonomicneuropathy
Insulin Neuritis/Treatment Neuropathy Ulnar -cubital tunnel Genitourinary autonomic neuropathy
Inflammatory Neuropathy Fibular -fibular head Hypoglycemia unawareness andassociated autonomic failure
Chronic inflammatory
demyelinating
polyneuropathy
Tibial -tarsal tunnel Sudomotor autonomic neuropathy
Mononeuritis multiplex
Lateral femoral
cutaneous -inguinal
ligament
Diabetic amyotrophy Ischemic:
Thoracic radiculopathies
Cranial nerve palsy (III,
VI, VII)
Dyck et al. 2011 [1] and Vinik et al 2003 [2]
Table 1. Classification of Diabetic Neuropathy
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Medicine, and the American Association of Physical Medicine and Rehabilitation is, “a
combination of neuropathic symptoms, multiple signs, and abnormal electrodiagnostic
studies” [8]. However, this does not distinguish typical DSP from atypical diabetic neuropa‐
thies [1]. A more precise definition for typical DSP proposed by neuromuscular experts at the
2011 Neurodiab Meeting suggested a tiered approach of possible, probable, confirmed and
subclinical DSP. Possible DSP includes symptoms or signs of DSP such as decreased distal
sensation or depressed ankle reflexes. Probable clinical DSP includes a combination of
symptoms and signs of DSP. Confirmed DSP includes symptoms, signs, and abnormal nerve
conduction study consistent with DSP (i.e. symmetric). Subclinical DSP would include patients
with abnormal nerve conduction studies but no signs or symptoms of neuropathy [1]. Debate
is ongoing as to whether abnormal skin biopsy with decreased epidermal nerve fiber density
should be considered with nerve conduction study as a confirmatory test.
3.3. Epidemiology
The prevalence of DSP in type 1 diabetes mellitus has been postulated to be over 50% by 25
years of diagnosis [9, 10]. These data depend on measures used for quantification. Nerve
conduction studies are typically more sensitive than monofilament tests and often show
decreased conduction velocity in sensory and motor nerves prior to the development of signs
or symptoms of sensory loss with monofilament and vibration testing [11]. More tests used,
and more sensitive measures will increase prevalence statistics.
Risk factors for DSP incidence and severity in addition to duration of diabetes and age are
hyperglycemia, systolic blood pressure, smoking, cholesterol, and height. The Diabetes
Control and Complications Trial confirmed hyperglycemia as a significant risk factor for DSP
in type 1 diabetes1. Interestingly, hyperglycemia alone has not been proven in prospective
cohort studies of type 2 diabetes to delay progression in this population [12] which raises the
question of whether hyperglycemia is the sole cause of DSP in type 2 diabetes.
Typical progression of DSP in type 1 is very slow, with incremental sensory loss over years
and decades. The Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications study data show minimal changes in conduction velocity
and amplitudes over 5 year periods, which can reassure patients [13, 14]. Progression typically
affects both large, myelinated fibers conveying tactile sensitivity, vibration and joint position
sense, and small, unmyelinated fibers conveying temperature and pain sensation. Motor
involvement is typically subclinical until later in the disease course. While slowed conduction
velocities, particularly in the fibular nerve, are common early signs of DSP, weakness typically
occurs later, first affecting the toes and then more proximal muscles.
Inflammatory neuropathies such as mononeuritis multiplex and diabetic amyotrophy
affecting the plexus are less common in type 1 diabetes than type 2 [15]. Chronic inflammatory
demyelinating polyneuropathy is also more common in type 2, but has not been shown to
1 *The DCCT was a groundbreaking study of patients with type 1 diabetes in the United States; a large, multicenter study
designed to test whether improved glycemic control delayed the onset or progression of diabetic complications. The
follow up epidemiologic study, EDIC (Epidemiology of Diabetes Interventions and Complications) continued to follow
the same patients enrolled in DCCT, which is still ongoing.
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affect diabetic patients at an increased rate than the general population [16]. Acute painful
neuropathy associated with weight loss and abrupt improvement in glycemic control occurs
in both type 1 and type 2 patients. This type of neuropathy, formerly known as “insulin
neuritis” typically has significant resolution within a year of onset [17].
Sensory symptoms include numbness, or alteration of sensation often described by patients
as “wearing multiple socks” or “walking on wood”. Neuropathic pain when present can vary
between sharp shooting pains, stabbing, or dull and aching. Muscle cramps in feet and legs
are common complaints. Hand symptoms can occur when DSP progresses to include the hands
in a length dependent process, but more commonly occur because of coexisting compression
neuropathies in the hands [18, 19].
Coexisting polyneuropathy from other causes also occurs in type 1 diabetes patients and can
account for as many as 10% of DSP cases [9]. The most common include alcoholic neuropathy,
B12 deficiency and monoclonal gammopathies. Atypical presentations such as severe distal or
proximal weakness, spasticity, faster progression over weeks to months should be signals that
a coexistent polyneuropathy may be present and needs evaluation.
3.4. Pathophysiology
The polyol pathway was put forth as a possible cause of diabetic neuropathy over 30 years
ago when aldose reductase inhibitors were first studied [20]. Since then, the pathophysiol‐
ogy of DSP in type 1 diabetes is still not completely known but several major pathways
have  been  the  focus  of  most  studies.  1)  increased  flux  through  the  polyol  pathway;  2)
advanced  glycation  end-products  affecting  proteins  and  lipids  [21,  22];  3)  increased
oxidative stress with impaired mitochondrial function [23, 24], 4) protein kinase C inhibi‐
tion [25, 26] and 5) loss of nerve growth factors [27, 28]. Additional mechanisms that have
been raised include  inflammation,  loss  of  nitric  oxide,  and hypoxia  from microvascular
damage  [29].  Additional  metabolic  factors  such  as  hypertriglyceridemia  may  be  more
pertinent to type 2 diabetes, although this also occurs in type 1 patients [30, 31]. Loss of
ATP and AMP production through mitochondrial  dysfunction may be a “final  common
pathway” for these mechanisms to cause neuronal injury [32].
The role of Schwann cells in DSP is still not completely understood. Schwann cells, not neurons
produce aldose reductase [33] and are also the source of nerve growth factors such as nerve
growth factor (NGF) and brain-derived neurotrophic factor [34, 35]. Schwann cells in culture
tend to be more resistant to hyperglycemia than neurons. However, the most recent evidence
suggests unmyelinated fibers to be more sensitive to hyperglycemia than myelinated fibers
[36]. These may have important implications for biomarkers in treatment studies.
3.5. Assessment
The assessment of DSP in type 1 diabetes significantly affects the sensitivity and specificity
cited. The simplest assessments used are loss of ankle deep tendon reflexes and detection of
pressure from a 10g monofilament. Monofilament sensitivity alone ranges from 20% to 64%
[37, 38] and likely improves if multiple sites on the foot are tested (8 sites recommended). Nerve
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conduction studies measuring sensory and motor nerve action potential amplitude, latency,
and conduction velocity are typically used for most studies [14]. The most common nerves
assessed are sural sensory and fibular motor nerves. These were shown by Dyck et al to be
involved earliest [39]. The earliest finding is conduction velocity slowing in the fibular and
sural nerves.
Additional  measures used include quantitative sensory testing,  which can be performed
with multiple devices to measure vibration and thermal thresholds [40,  41].  This can be
more  sensitive  than  nerve  conduction  studies  but  is  subjective  and  not  well  suited  for
diagnostic purposes [42]. Quantitative sensory testing is highly reproducible and has been
used  in  several  clinical  neuropathy  studies  [43,  44].  Sural  nerve  biopsy  is  rarely  per‐
formed for diagnosis due to its invasiveness (and cannot be repeated) and is usually used
to  evaluate  for  other  forms of  neuropathy  such  as  chronic  inflammatory  demyelinating
polyneuropathy,  vasculitis,  or  inherited neuropathies.  Skin biopsy with measurement  of
intraepidermal nerve fiber density has become more common, especially when combined
with chemical axotomy with capsaicin to measure nerve regeneration [36]. Newer noninva‐
sive  methods  used include  confocal  microscopy of  corneal  C  fibers  [45]  or  of  Meissner
corpuscles (mechanoreceptors) in the finger [46, 47].
3.6. Management
Management of DSP is largely supportive. The main therapeutic aim is to achieve normogly‐
cemia or HgA1c less than 7 [13]. This can be accomplished with frequent self-monitoring and
using insulin pumps for continuous subcutaneous insulin infusion or multiple daily injections.
Both the EURODIAB and the Diabetes Control and Complications Trial confirmed therapeutic
efficacy in delaying progression of DSP with lower glycemic levels [5, 13]. For treatment of
insulin neuritis, management is largely supportive and usually requires relaxing hyperglyce‐
mia control somewhat. Inflammatory neuropathies may respond to pulsed IV steroids and
intravenous immunoglobulins but class A evidence is still lacking [48, 49]. Diabetic chronic
inflammatory demyelinating polyneuropathy is managed similarly to idiopathic chronic
inflammatory demyelinating polyneuropathy [50].
Foot care is critical once DSP occurs. Patients should be instructed to inspect their feet every
night for new ulcerations, blisters or cuts. Wearing shoes at all times will also decrease the
chance of potential injury. Feeling bathwater with hands or more proximal leg is also helpful
to avoid burns from insensate feet. As neuropathy occurs, the foot structure will change due
to muscle atrophy and due to fractures from insensate feet (Charcot foot). Orthotic inserts may
be helpful in preventing further ulceration and stabilizing the feet [51].
Falls are an important complication in DSP and need to be screened for at clinic visits.
Evaluation by a physical therapist can be helpful in identifying whether a cane, four-point
canes, walkers, wheelchairs should be singular. Home evaluations to improve lighting,
minimize obstructions and irregular floors like loose rugs are also important. Adding grab
bars in bath areas and minimizing steps can be helpful changes to homes.
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3.7. Treatment of neuropathic pain
A significant number of patients with DSP (16-60%) have symptoms of neuropathic pain [52,
53]. One UK study suggested that painful symptoms were more prevalent in type 2 than type
1 diabetes [53]. Typical pain symptoms are delayed compared to signs of neuropathy in type
1 diabetes [54, 55]. The etiology of neuropathic pain in DSP has been thought to be due to
abnormalities in C-fiber nerve endings causing aberrant signaling through protein kinase C
[26], increased transient receptor potential vanilloid 1 expression [56], dysregulation of ion
channels [57], abnormal nerve growth factor levels [58] and possibly dysregulation of de‐
scending pain pathways [59].
Typical pain symptoms described include “burning”, “stabbing”, “needle-like”, “shooting”,
“electric” etc. Patients often complain of allodynia, e.g. normal sensations become painful such
as the touch of bedcovers to the feet, as well as hyperalgesia (painful sensations such as
pinprick are unbearably painful). Pain is typically worse at night, and with activities such as
walking and standing. Mononeuropathies such as carpal tunnel syndrome can also cause
nocturnal paresthesias. Pain symptoms are typically not completely relieved with medications.
Pain can be moderate to severe with an average of 5.8/10 on a pain scale [60].
Medications used for neuropathic pain include traditional pain medications such as opioids
and tramadol, antiepileptic agents and antidepressants (Table 2) [61]. Typically patients
require large doses of opiates for pain relief, and long acting opiates are preferred to provide
sustained relief. Sedation, constipation, pharmacologic tolerance and addiction issues are
significant barriers and usually prohibit opiates as first line pain treatment in neuropathic pain.
Mexiletine, a sodium channel blocker and anti-arrhythmic agent has also been shown to have
some analgesic effects [62].
Alpha2-delta inhibitors gabapentin and pregabalin are the most commonly used anti-epileptic
medications. These medications act at the dorsal horn of the spinal cord to inhibit voltage gated
calcium channels [63, 64]. The advantage of gabapentin and pregabalin is their renal excretion
and lack of interaction with other medications. Main side effects include drowsiness, dizziness,
peripheral edema, weight gain, and myoclonic jerks at higher doses. Gabapentin is typically
initiated at 300 mg up to three times a day and can be escalated up to 4800 mg in divided doses.
Its short half-life requires three to four times a day dosing for optimal pain relief. Pregabalin
has a longer half-life and is typically dosed twice a day although some patients benefit from
dosing three times a day. Pregabalin is usually started at 75 mg twice a day and titrated up to
300 mg twice a day. Consultation with a nephrologist in dialysis dependent patients is needed
due to renal excretion, but does not preclude use in these patients. Typically nephrologists will
administer one dose after dialysis. Other anticonvulsants used for neuropathic pain include
carbamazepine, oxcarbazepine, valproic acid, lamotrigine, lacosamide, and phenytoin.
Antidepressants acting on norepinephrine such as tricyclic antidepressants and the selective
serotonin and norepinephrine reuptake inhibitor duloxetine are also helpful in treating
neuropathic pain [65, 66]. Duloxetine is well tolerated, with few side effects. Caution should
be used in patients with renal insufficiency as elevations of systolic blood pressure have been
observed. Nausea can occur initially, but can be avoided with initiation at lower doses such
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as 20 -30 mg and slow titration up to 60 mg. Effectiveness of 120 mg was not statistically
different from 60 mg in clinical studies, although some patients report improved benefit at
higher doses [65]. Tricyclic antidepressants also have a benefit in patients reporting difficulty
initiating sleep due to pain due to their sedating effects. Dosages of 25-100 mg amitriptyline 2
hours before bedtime are typically used. At higher doses and in elderly patients, an ECG
should be obtained because of possible effects of tricyclics on QT prolongation and heart block.
Side effects include drowsiness, urinary hesitancy, constipation, orthostatic hypotension and
erectile dysfunction.
Topical creams are not typically efficacious for painful DSP. Capsaicin cream/patch has shown
efficacy [67], but is typically not well tolerated due to the significant initial pain with applica‐
tion. Gloves need to be worn and avoidance of the eyes is necessary. Occasionally 1% lidocaine
patches can be helpful in patients with focal mononeuropathies such as meralgia paresthetica
(compression of the lateral femoral cutaneous nerve). Topical compounded creams containing
gabapentin, amitriptyline, and ketamine have been used but there are no published reports on
efficacy in placebo controlled studies.
Anti-Epileptic Medications Anti-Depressants Other
Gabapentin Tricyclic antidepressants (amitriptyline,nortriptyline, imipramine) Opiates
Pregabalin* Duloxetine* Tramadol
Carbamazepine Mexiletine
Lamotrigine Capsaicin Cream/Patch
Alpha lipoic acid
*FDA approved indication for diabetic neuropathic pain.
Table 2. Pharmacologic Treatments of Neuropathic Pain
4. Focal neuropathies
4.1. Overview and epidemiology
Other types of neuropathy which can occur include mononeuropathies, typically at compres‐
sion points such as median mononeuropathy at the wrist, e.g. carpal tunnel syndrome, ulnar
neuropathy at the elbow, and peroneal neuropathy at the knee. In the Rochester Diabetes Trial,
these occurred at about the same frequency or higher in type 1 vs. type 2 patients [9]. Cranial
neuropathies and truncal radiculopathy occur at an increased rate in diabetic patients, but
prevalence data for type 1 and type 2 patients is not available. Pain is a common presenting
symptom in ischemic ocular motor palsies and thoracic radiculopathies in diabetes [68, 69].
The Veterans Affairs study of type II patients showed decreased prevalence of cranial mono‐
neuropathies with stricter glucose control but data is lacking for type 1 patients [70]. It is not
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uncommon for mononeuropathies to occur prior to the development of DSP or identification
of diabetes, particularly in type 2 patients [71, 72]. This has not been described in type 1 patients.
Median mononeuropathy at the wrist, e.g. carpal tunnel syndrome is the most common
mononeuropathy in diabetes and occurs three to four times as commonly in diabetics com‐
pared to healthy controls, and is more common in diabetics with DSP than without [72-74].
Median mononeuropathy has been reported as early as 11 years old [75]. Risk factors for
development of carpal tunnel syndrome include obesity and lipid-lowering medications [74].
4.2. Pathophysiology
The pathophysiology of mononeuropathies in diabetes is not well understood. They are
generally divided into compression-site mononeuropathies, occurring at typical compression
points such as the transverse ligament in the wrist (median), cubital tunnel (ulnar nerve), across
the knee (fibular nerve), the inguinal ligament (lateral femoral cutaneous nerve/meralgia
paresthetica) and tarsal tunnel (tibial nerve). Cranial nerve mononeuropathies and thoracic
radiculopathies, diabetic amyotrophies are thought to have an ischemic etiology, either due
to microvascular disease (such as cranial nerve involvement) or inflammation (diabetic
amyotrophy). Some patients (described in type 2 diabetes) have a rapid development of
multiple mononeuropathies which is indistinguishable from a vasculitic mononeuritis
multiplex in presentation and can be associated with inflammation on biopsy [76].
The greater prevalence of compression mononeuropathies in diabetes (20-30% of Type 1 and
2 patients) [9, 77] has been observed for decades, but the pathophysiology is not well known.
Experimental compression neuropathies trigger Schwann cell proliferation, apoptosis causing
local demyelination then remyelination. This occurs prior to the development of axonal
degeneration [78]. The median nerve when visualized with ultrasonography is larger in
patients with compression compared to healthy controls which may be due to remyelination
[79]. It has been presumed that hyperglycemia injured nerves are more vulnerable to com‐
pression than normal nerves. Another possibility is lack of symptoms in the diabetic may make
compression mononeuropathies worse because of delayed recognition [77]. Other possible
etiologies include greater edema within the nerve and diabetic cheiroarthropathy (thickening/
fibrosis of the flexor synovium from excessive connective tissue) [80, 81].
4.3. Assessment
Identification of mononeuropathies may be based on signs and symptoms localizable to a
specific nerve in a diabetic patient (e.g. ptosis, diploplia in a Cranial nerve III/oculomotor nerve
palsy). This is typically the case for cranial nerve palsies, optic neuropathies, thoracic radicu‐
lopathies, or lateral femoral cutaneous nerve palsy where the distribution of deficit is patho‐
gnemonic. If the symptoms and signs are specific to one cranial nerve in a previously diagnosed
diabetic patient, imaging with magnetic resonance imaging, CT or other modality is typically
not needed to confirm the diagnosis. Especially in cranial nerve III palsies, there is controversy
whether imaging should occur in a diabetic patient with a classical papillary-sparing presen‐
tation [82, 83].
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Mononeuropathies may be identified on testing with nerve conduction studies. This is more
common in carpal tunnel syndrome, ulnar mononeuropathy, and fibular mononeuropathy
which are often asymptomatic. Nerve conduction studies in compression mononeuropathies
distally typically demonstrate slowing of conduction velocity across the compressed segment
(ulnar, fibular, tibial nerve) or increased distal latency compared to nearby nerves (median
nerve). Multiple nerves are often compared, or side to side comparisons are made to exclude
underlying DSP.
For  carpal  tunnel  syndrome,  nerve  ultrasound has  become a  more  common procedure,
demonstrating enlarged median nerve cross sectional area in the wrist in affected individ‐
uals  compared to  controls  [84].  Thus far,  no differentiation between ultrasound appear‐
ance of diabetic vs. non-diabetic nerves have been found [85]. Another study suggested a
larger cross-sectional area of the tibial nerve at the tarsal tunnel in diabetic patients [86].
Further studies are still needed on the utility of this measure for diabetic patients. Magnet‐
ic resonance imaging is also used for assessment of carpal tunnel syndrome, but data in
diabetes vs. control patients is lacking and cost is significantly higher than nerve conduc‐
tion studies or ultrasound [87].
4.4. Treatment
Treatment of compression induced mononeuropathies is aimed at relieving the site of trauma.
Bracing, avoiding extenuating activity, and changing postures are initial non-surgical ap‐
proaches. Data for surgical approach to compressive neuropathy is better known in median
mononeuropathies at the wrist (carpal tunnel syndrome) because of larger reported cohort
studies. However, data are conflicting in regards to outcome of carpal tunnel syndrome
surgical release with some studies showing poorer outcomes and some not significantly
different from non-diabetic patients [88, 89]. This may occur due to differences in patient
selection. Results of surgical release of the ulnar nerve at the cubital tunnel, the second most
common mononeuropathy (2.1%) are worse compared to carpal tunnel syndrome [81, 90]. It
is not clear whether this is due to underlying diabetic polyneuropathy or due to patient
selection bias (misdiagnosis).
Treatment of ischemic induced mononeuropathies is typically supportive. Pain management
is often needed for thoracic radiculopathies, meralgia paresthetica (lateral femoral cutaneous
nerve palsy). Prisms or patching can be used for diploplia in ocular motor cranial nerve palsies
(cranial nerve 3, 4, and 6). Taping of the eyelid and lubrication may be needed in facial nerve
palsies to prevent corneal abrasion. Little data are available for prognosis. Many patients
improve over 3-6 months, but some may have permanent muscle weakness or ptosis [91, 92].
Treatment with intravenous alpha-lipoic acid has also been reported as improving outcomes
but was not placebo controlled [93]. Otherwise, treatment for mononeuropathies in diabetes
is not significantly different than in non-diabetics.
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5. Diabetic autonomic neuropathy
5.1. Overview
Autonomic neuropathy is a form of peripheral neuropathy affecting the nerves of the auto‐
nomic nervous system. Autonomic neuropathy most commonly affects organs of the cardio‐
vascular, gastrointestinal, urinary, and reproductive systems, although any system of the body
may be affected. Its etiology is poorly understood, but as with other forms of peripheral
neuropathy long exposure to hyperglycemia, advanced glycation end products, vascular
hypoxia [94], and activation of the polyol pathway are thought to play major roles. Typical
signs and symptoms depend on the organ affected, but include resting sinus tachycardia
without sinus arrhythmia, orthostatic hypotension, delayed gastric emptying, diabetic
diarrhea, constipation, erectile dysfunction, bladder dysfunction, hypoglycemia unawareness,
distal hyperhidrosis or anhidrosis, facial sweating, and gustatory sweating. Cardiovascular
autonomic neuropathy is life threatening and carries a high risk of mortality [2, 95, 96].
5.2. Epidemiology
The  prevalence  of  autonomic  neuropathy  in  type  1  diabetes  populations  varies  widely
depending on duration of diabetes and method of assessment, with prevalences ranging
from 2.6% in individuals with short duration of diabetes [97] to 90% in pancreatic trans‐
plant  candidates  [98].  Defining autonomic  neuropathy based on an abnormal  heart  rate
response  to  deep  breathing  and  the  presence  of  at  least  two  autonomic  neuropathy
symptoms, the prevalence ranged from 3.7% to 11.3%, with a decreasing trend with higher
BMI,  in  the  Pittsburgh  Epidemiology  of  Diabetes  Complications  (EDC)  when the  mean
duration of diabetes was approximately 20 years [96]. In a subgroup of this same cohort
twenty years later, when mean diabetes duration was 40 years, the prevalence of autonom‐
ic neuropathy based on an abnormal response to deep breathing was 61% [99]. In the entire
EDC  cohort,  the  incidence  of  autonomic  neuropathy  based  on  an  abnormal  heart  rate
response  to  deep  breathing  and  the  presence  of  at  least  two  autonomic  neuropathy
symptoms was 0.78 per 100 person years of duration of diabetes, with a lower incidence
for  a  given  duration  of  diabetes  in  more  recently  diabetes  diagnosed  cohorts  in  the
Pittsburgh Epidemiology of Diabetes Complications study [100].  In the Diabetes Control
and Complications Trial/ Epidemiology of Diabetes Interventions and Complications study
population, which because of inclusion criteria was a healthier cohort at study baseline than
the EDC population, the prevalence of autonomic neuropathy at the follow-up years 13/14
of Epidemiology of Diabetes Interventions and Complications study, representing approx‐
imately 27 years of duration of type 1 diabetes, was 29% and 35% in the former intensive‐
ly treated and conventionally treated Diabetes Control and Complications Trial participants
[10]. The presence of diabetic autonomic neuropathy is associated with poor prognosis. In
the  EDC  study,  mortality  during  20  years  of  follow-up  was  increased  2.43-fold  after
controlling for age, sex, BMI, and other late complications [96].
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5.3. Pathophysiology
Diabetic autonomic neuropathy is a neuropathic disorder of the peripheral nervous system in
individuals with diabetes or prediabetes. The pathogenesis of diabetic autonomic neuropathy
is poorly understood, but long exposure to hyperglycemia [94, 101], advanced glycation end
products [2, 94, 101], vascular insufficiency [2, 94], and activation of the polyol pathway [2, 94,
101] have been long thought to play major roles. The nerves of the autonomic nervous system
innervate every organ of the body and as such any organ system can be affected by diabetic
autonomic neuropathy. Disorders resulting from damage to autonomic nerve fibers are
typically classified into the following syndromes: cardiovascular autonomic neuropathy
(CAN), gastrointestinal, genitourinary, hypoglycemia unawareness, and sudomotor.
5.3.1. Pathogenesis
Long exposure to hyperglycemia is one of the strongest hypotheses on the etiology of diabetic
peripheral neuropathy. In individuals with type 1 diabetes, results from the Diabetes Control
and Complications Trial showed significantly lower declines in the R-R interval over time in
those in the intensive therapy arm of the trial [97]. Whether this was due to lower levels of
hyperglycemia was not specified. There was a low incidence of CAN in both treatment arms
(4% in the intensive group and 9% in the conventional group), with a 45% lower incidence in
the treatment arm [10]. Follow-up of the entire cohort thirteen to fourteen years after the close-
out of the trial revealed a marked increase in the prevalence of CAN in the entire cohort, which
was significantly greater in the former conventional therapy group. Differences in HbA1c
accounted for the majority of the group differences in the incidence of CAN [102]. The
beneficial effect of former intensive therapy on the incidence of neuropathy appeared to be
greater for CAN than for distal symmetrical polyneuropathy, suggesting that the detrimental
effect of hyperglycemia may be greater on small nerve fibers than large nerve fibers [10].
Mechanisms by which hyperglycemia may cause nerve damage include activation of the
polyol pathway and accumulation of advanced glycation end products [2, 94, 101].
5.3.2. Cardiovascular Autonomic Neuropathy (CAN)
Cardiovascular autonomic neuropathy results from damage to the nerves that innervate the
heart and coronary blood vessels. Because of its clinical importance, it has been the most
studied of all of the diabetic autonomic neuropathy syndromes. It is the most life threatening
of all of the diabetic autonomic neuropathy syndromes and carries a high risk of mortality.
Signs/symptoms of CAN include orthostatic hypotension, sinus tachycardia, exercise intoler‐
ance, silent myocardial infarction, and sudden death.
Autonomic nervous system innervation of the heart largely regulates heart rate variability. In
diabetes, cardiac autonomic nervous system dysfunction generally progresses from the apex
to the base of the heart [103]. Diabetic autonomic neuropathy appears to affect the long nerve
fibers first [2]. In CAN, autonomic dysfunction is usually observed first as a decrease in
parasympathetic activity, reflecting damage to the vagal nerve, the longest of the autonomic
nerve fibers, and a compensatory increase in sympathetic autonomic nervous system activity
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[103]. Sympathetic activity increases heart rate while parasympathetic activity decreases heart
rate. The decline in parasympathetic activity is reflected in the decline in variation in heart rate
with inspiration and expiration, where there is less of a decline in heart rate with expiration.
A decline in heart rate variability is one of the earliest manifestations of CAN [103]. This
compensatory increase in heart rate with parasympathetic denervation also manifests in an
increased resting heart rate, and rates may reach greater than 100 beats per minute [103], resting
sinus tachycardia.
Autonomic innervation of the heart also regulates blood pressure. The apparent early vagal
denervation in CAN results in increased sympathetic nervous system activity, partially due
to the counter-regulatory activity of the parasympathetic neurons, increasing blood pressure.
During sleep, this is reflected in the “non-dipping” pattern of blood pressure often observed
in individuals with type 1 diabetes [104, 105]. This lack of nocturnal bradycardia is associated
with prolongation of the heart rate corrected Q-T interval in adolescents with type 1 diabetes
[106], although Stella et al [105] observed no cross-sectional association between “non-
dipping” and CAN in adults with type 1 diabetes. Later cardiac sympathetic denervation
results in loss in the normal heart rate and blood pressure responses to exercise. The normal
increase in heart rate and blood pressure and subsequent increased cardiac output is impaired,
reducing exercise tolerance [2, 103]. Sympathetic cardiac denervation also manifests as
orthostatic hypotension, a prolonged drop in blood pressure upon standing due to reduced
baroreceptor stimulated sympathetic increase in heart rate and vasoconstriction of splanchnic
vascular beds. Orthostatic hypotension may often be asymptomatic, but can result in dizziness,
syncope, falls and fractures.
CAN is associated with silent myocardial  ischemia and infarction [2,  107],  and carries a
high  risk  of  mortality  [95,  96].  The  association  of  diabetic  CAN with  silent  myocardial
infarction is likely due to the higher frequency of silent myocardial ischemia in individu‐
als with diabetic CAN [2]. Damage to the myocardial sensory afferent fibers may reduce
the sensation of ischemic pain [2]. A meta-analysis of twelve studies of individuals with
diabetes  showed  a  2-fold  higher  risk  of  silent  ischemia  in  those  with  CAN  [2].  In  a
population  of  middle-age  and  elderly  individuals  with  type  1  diabetes,  poorer  cardiac
autonomic function predicted future coronary heart disease events [108].  Perhaps due to
its  association  with  silent  myocardial  ischemia,  cardiovascular  disease,  resting  tachycar‐
dia, and exercise intolerance, CAN greatly increases the risk of sudden death [109-111]. We
have shown in individuals with long-standing type 1 diabetes that CAN as diagnosed based
on heart rate variability and in the presence of at least one other symptom of autonomic
neuropathy was a significant predictor of mortality,  independently of distal symmetrical
polyneuropathy and other late complications of diabetes [96].
5.3.3. Gastrointestinal autonomic neuropathy
Diabetic autonomic neuropathy affecting the gastrointestinal system may result in gastropa‐
resis, esophageal dysfunction, diarrhea, fecal incontinence, or constipation. Gastroparesis, or
delayed gastric emptying, is common in type 1 diabetes, with prevalence rates from approxi‐
mately 30 to 50% [4, 112-114] and appears to be more prevalent in type 1 than in type 2 diabetes
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[115]. Symptoms of gastroparesis include nausea, vomiting, anorexia, bloating, early satiety,
and wide swings in blood sugar [112]. hyperglycemia delays gastric emptying [116] while
hypoglycemia accelerates it [117]. Esophageal dysfunction is thought to result from a combi‐
nation of impairment of vagal nerve and enteric nervous system innervation of esophageal
smooth muscle cells regulating peristalsis [117]. Symptoms of esophageal dysfunction include
difficulty swallowing (dysphagia) and heartburn. Peristalsis dysmotility of the lower gastro‐
intestinal track can result in diarrhea or constipation, both very commonly observed in type 1
diabetes. The diarrhea may be due to bacteria overgrowth resulting from bowel stasis, very
rapid peristalsis, or both. Very slow peristalsis activity may result in constipation. Fecal
incontinence results from poor anal sphincter tone and impaired rectal sensation [2].
5.3.4. Genitourinary autonomic neuropathy
Autonomic nerve dysfunction or damage affecting the genitourinary system may manifest as
erectile and/or ejaculation dysfunction or failure in males, dyspareunia in females, and bladder
dysfunction, in both genders. Autonomic neuropathy affecting the reproductive organs
manifests as erectile and ejaculation failure in males and reduced sexual arousal, reduced
vaginal lubrication and painful intercourse in females. Autonomic neuropathy affecting the
urinary tract may result in decreased frequency of urination and increased urinary tract
infections, increased post void residual volume, dribbling, and urinary incontinence [118, 119].
Erectile dysfunction in diabetes may be due to one or any combination of the following:
neuropathy, atherosclerosis, changes in corporal erectile tissue including deposition of AGEs,
anti-hyperglycemic medications, and psychological factors, although neuropathy appears to
be the predominate cause [119]. The corpus cavernosum is innervated by both sympathetic
and parasympathetic nerve fibers and sensory and somatic nerve fibers [120, 121]. The
neurogenic basis of erectile dysfunction is a decrease in smooth muscle relaxation of the corpus
cavernosum [119, 122], inadequate nitric oxide synthase activity [119, 122], impaired sensation
of the glans penis [119, 120], and abnormal motor function of erectile tissue [119].
Little is known about the pathogenesis of sexual dysfunction in women. It is characterized by
reduced sexual arousal, atrophic vaginitis and subsequent painful intercourse. It is poorly
related to glycemic control, age, duration of diabetes, or diabetes complications [123], but
appears to be related to depression and to improve with estrogen creams [118]. In a substudy
of the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and
Complications cohort examining female sexual dysfunction in 424 women with type 1 diabetes
and a mean age of 42.8 years, the prevalence of female sexual dysfunction was 35% [124].
Bladder dysfunction is one of the most common complications of diabetes, affecting a large
proportion of the type 1 diabetic population [117] and occurring early in the disease process.
The diabetic neurogenic bladder is caused by degeneration of both afferent myelinated and
efferent non-myelinated nerve fibers to the bladder. Afferent nerve fiber degeneration results
in reduced sensation of a full bladder [125]. Efferent nerve fiber degeneration results in reduced
frequency of micturition, incomplete emptying of the bladder, i.e. increased post-void residual
volume, and eventually urinary incontinence [125]. The neurogenic bladder is associated with
recurrent urinary tract infections [125] and may lead to renal failure/disease.
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5.3.5. Hypoglycemia unawareness and associated autonomic failure
Autonomic neuropathy is associated with more severe hypoglycemic events [126, 127] and the
loss of symptoms prompting awareness of hypoglycemia [128, 129]. However, the jury is still
out on whether autonomic neuropathy actually causes a loss of counter-regulatory responses
to hypoglycemia [130]. Hypoglycemia associated autonomic failure (HAAF) can occur in the
absence of autonomic neuropathy [126, 131, 132]. Conversely, diabetic autonomic neuropathy
is observed in the absence of hypoglycemia symptom loss [131, 133]. Additionally, reversal of
hypoglycemia symptom awareness is observed after strict avoidance of hypoglycemia for a
relative short period of times, i.e. several weeks to months [134-136]. This would all appear to
suggest that autonomic neuropathy is not a causative factor in hypoglycemia unawareness,
i.e. the loss of the counter-regulatory responses to hypoglycemia. However, in the presence of
autonomic neuropathy and in combination with HAAF a greater reduction in counterregula‐
tory response hypoglycemia is observed than in hypoglycemia unawareness without auto‐
nomic neuropathy [130]. Furthermore, the recovery of hypoglycemia awareness symptoms
with strict avoidance of hypoglycemia is not as complete in those with autonomic neuropathy
[128]. Even with the recovery of awareness symptoms, the epinephrine response to hypogly‐
cemia is only partially recovered and even less so in those with autonomic neuropathy [130].
In aggregate, this suggests that autonomic neuropathy is not the predominate cause of
hypoglycemia unawareness but does enhance its severity and may play a partial etiologic role.
5.3.6. Sudomotor autonomic neuropathy
Abnormalities in thermoregulation are common in type 1 diabetes [137, 138]. The sweat glands
are innervated by sudomotor postganglionic unmyelinated sympathetic c-fibers. Autonomic
neuropathy affecting sudomotor nerve function results in both anhidrosis and hyperhidrosis.
Sudomotor dysfunction manifests symptomatically as dry scaly skin of the limbs and appen‐
dages, heat intolerance, and gustatory sweating. With increasing duration of diabetes,
anhidrosis becomes more severe, progressing in a distal to proximal direction [118]. Gustatory
sweating, in which there is excessive sweating in the face and trunk in response to eating is
thought to result from imperfect reinnervation of postganglionic sudomotor C-fibers following
denervation [118].
5.4. Assessment
Assessment of cardiovascular autonomic nervous system function can be done by measuring
heart rate variability, the heart rate response in postural change from lying or sitting to
standing, the blood pressure change from lying or sitting to standing, and the diastolic blood
pressure response to a sustained hand grip. Heart rate variability can be assessed my meas‐
uring the heart rate response to paced deep breathing, the Valsava maneuver, and spectral
analysis. The heart rate response to deep breathing and the heart rate response to a change in
posture to the standing position predominately reflect parasympathetic function [2]. The heart
rate response to the Valsalva maneuver reflects both parasympathetic and sympathetic
function fairly equally [2]. The change in blood pressure from a lying or sitting position to a
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standing position and the blood pressure response to a sustained hand grip reflects sympa‐
thetic nervous system function [2].
Assessment of autonomic neuropathy affecting the gastrointestinal track can be done by
endoscopy and scintographic measurement of esophageal bolus transit time for esophageal
dysfunction; scintography, isotope breath tests, and ultrasonography for gastroparesis;
hydrogen breath test for diabetic diarrhea; barium enema for constipation; and anorectal
manometry, endoanal ultrasonography, colon transit tests, digital examination of the rectum,
protoscopy and sigmoidoscopy for fecal incontinence [2, 139].
Erectile dysfunction can be assessed by taking a case history, such as with the International
Index of Erectile Dysfunction, by physical examination including examining of external
genitalia, blood tests including measurement of testosterone levels, measurement of nocturnal
penile tumescence, and Doppler studies [2, 117, 140]. The Female Sexual Function Index has
been used to evaluate sexual dysfunction in women with type 1 diabetes [124]. Vaginal
plethysmography has also been used to directly assess vaginal lubrication in women with
diabetes [141].
Post void residual volume can be assessed by transurethral catherization or non-invasively
via ultrasound [142]. Bladder sensation and upper urinary tract dilation can be assessed with
cystometry and voiding cystometrogram. Uroflometry can be used to assess urinary flow rate
and sphincter function. A urine culture should also be done to assess bacteria cystitis. In
women, a urogynecological examination should be done in order to exclude pelvic prolapse.
Assessment of sudomotor function can be done with the Quantitative Sudomotor Axon Reflex
Test (QSART), thermoregulatory sweat test, or the sympathetic skin response. The thermo‐
regulatory sweat test can be used to assess the pattern and distribution of anhydrosis [143].
The QSART is used to assess postganglionic sudomotor nerve function [119, 143]. The
sympathetic skin response assesses postganglionic sudomotor sympathetic nerve fibers [144].
5.5. Management
Treatment  and  management  of  diabetic  autonomic  neuropathy  includes  tight  glycemic
control  [4];  however,  the primary focus is  on alleviation of  symptoms [4,  101].  Manage‐
ment of orthostatic hypotension consists of educating the patient in strategies to avoid or
address reversible causes of hypotension, increased fluid and salt consumption supplement‐
ed with mineralocorticoid therapy, pharmacotherapy with sympathomimetic agents,  and
wearing clothing such as compression stockings that increase venous return [2, 101, 118].
Antioxidants  and  cardioselective  beta-blockers  may  be  beneficial  in  cardiac  autonomic
neuropathy [2].
For  patients  with  esophageal  dysmotility,  proton  pump  therapy  is  conventionally  used
[119]. Fluid consumption immediately after consumption of medications should be advised
in  order  to  avoid  pill-induced  esophagitis  in  these  patients  [119].  Diets  low  in  fat  and
soluble fiber may be beneficial in patients with gastroparesis [2, 119], although pharmaco‐
therapy with prokinetic agents is the mainstay of therapy [119]. Insulin pump therapy may
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also  help  to  improve  symptoms  in  type  1  diabetic  patients  with  gastroparesis  [119].
Antibiotic therapy is beneficial in the treatment of diarrhea [2, 119].
Treatment of bladder dysfunction may be behavioral, pharmacological, or surgical. Behavioral
management includes pelvic floor exercises to strengthen the muscles of the pelvic floor that
support the bladder and urethretha. It also includes a program of scheduled fluid intake and
micturition, manual procedures such as the Crede’s maneuver, pelvic tapping, the Valsava
maneuver, and clean intermittent self-catheterization. Pharmacotherapy includes the use of
antimuscarinic agents, cholinergic agents, and tricyclic antidepressants. In cases refractory to
non-pharmacological and pharmacological treatment, surgical procedures such as vesicle neck
resection, selective pudendal nerve block, unilateral pudendal neurectomy, and sacral
neuromodulation may be beneficial [2, 119, 142, 145].
Treatment and management of erectile dysfunction should include psychological counseling;
however, pharmacotherapy with the PDE5 inhibitors (sildenafil, vardenafil, tadalafil) is the
mainstay of therapy. Intracavernous or intraurethral injections with vasoactive medication,
vacuum constriction devices, and penile prosthesis implantation are also options [2, 119].
Vaginal estrogen creams in has been shown to be beneficial in diabetic women with female
sexual dysfunction [118].
6. Conclusion
Peripheral and autonomic neuropathy is a common complication of type 1 diabetes with
significant  morbidity  and  mortality.  Fortunately,  aggressive  hyperglycemia  control  can
delay the onset and minimize the severity of neuropathy in this population.  The patho‐
physiology of neuropathy is complex and likely involves multiple mechanisms, which may
be the reason for lack of efficacious treatments beyond glucose control. Early recognition
of peripheral and autonomic neuropathy is also important to decrease amputation risk and
mortality.
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